Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

Cancer

Volumn 103, Issue 4, 2005, Pages 802-809

  Biemond Ter Stege, Elize M ^a   Kros, Johan M ^a   De Bruin, Hein G ^a   Enting, R H ^a   Van Heuvel, Irene ^a   Looijenga, Leendert H J ^a   Van Der Rijt, Carin D D ^a   Smitt, Peter A E Sillevis ^a   Van Den Bent, Martin J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

19q; 1p; Chemotherapy; Fluorescence in situ hybridization; Low grade; Oligoastrocytoma; Oligodendroglioma

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; DIARRHEA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE PROBE; HUMAN; HUMAN TISSUE; LIVER TOXICITY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LOMUSTINE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROCARBAZINE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 13444265882     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20828     Document Type: Article

References (24)

1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol. 1994;12: 2013-2021.
2. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU and vincristine chemotherapy. Neurology. 1998;51:1140-1145.
3. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma: the European Organization of Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol. 2003;21:2525-2528.
4. Mason WP, Krol GS, DeAngelis LM. Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996;46:203-207.
5. Buckner JC, Gesme D, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and and associations with chromosomal abnormalities. J Clin Oncol. 2003;21:251-255.
6. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14:1715-1721.
7. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003;21:646-651.
8. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low grade glioma: clinical benefits and radiological response. Ann Oncol. 2003;14:1722-1726.
9. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
10. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytoma, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645.
11. Bauman GS, Ino Y, Yeki K, Fisher BJ, Louis DN, Cairncross JG. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendroglioma. Int J Radiat Oncol Biol Phys. 2000;48:825-830.
12. van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer. 2003;97:1276-1284.
13. Lantos PL, Bruner JM. Gliomatosis cerebri. In: Kleihues P, Cavenee WK, editors. Pathology and genetics. Tumours of the nervous system. Lyon: IARC, 2000:92-93.
14. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
15. Stock C, Ambros IM, Mann G, Gadner H, Amann G, Ambros PF. Detection of 1p36 deletions in paraffin section of neuroblastoma tissues. Genes Chromosomes Cancer. 1993;6:1-9.
16. Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related fators on mid-term to long-term cognitive sequelae in low grade gliomas: a comparative study. Lancet. 2002;360:1361-1368.
17. Gregor A, Cull A, Traynor A SM, Lander F, Love S. Neuropsychometric evaluation of long term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol. 1996;41:55-59.
18. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. 2001;7:839-845.
19. Vos MJ, Hoekstra OS, Barkhof F, et al. Thallium-201 single-photon emmision computed tomography as an early predictor of outcome in recurrent glioma. J Clin Oncol. 2003; 21:3559-3565.
20. Derlon JM, Chapon F, Noël MH, et al. Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology. Eur J Nucl Med. 2000;27:778-787.
21. Ribom D, Eriksson A, Hartman M, et al. Positron emission tomograpy 11C-methionine and survival in patients with low-grade gliomas. Cancer. 2001;92:1541-1549.
22. 11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med. 1997;38:517-522.
23. Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment in low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer. 2004;90:781-786.
24. Karim ABMF, Afra D, Bleehen NM, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys. 2002;52:316-324.